fashion -WSS

fashion

author：Wikipedia 2025-09-06 04:33:47 - browse：681

Jakub Porzycki/NurPhoto via AP

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business.

The need-to-know this morning

Apellis Pharmaceuticals said a European advisory committee is expected to recommend against the approval of Syfovre, its eye drug for a common form of blindness. The company plans to appeal the negative ruling.
Sage Therapeutics and Biogen announced the commercial launch of Zurzuvae, an oral treatment for women with postpartum depression.
Merck and Moderna reported three-year follow-up data on their mRNA-based immunotherapy for advanced melanoma. Phase 3 studies are underway.
The FDA accepted Amgen’s marketing application for tarlatamab, a bispecific antibody to treat advanced small cell lung cancer. The approval decision date is June 12, 2024.

Is it time to worry about Moderna?

Yesterday’s news that Pfizer is expecting to sell far fewer Covid-19 vaccines than Wall Street expected sent shares of Moderna down as much as 6% on fears that the company could be in for a painful revision of its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

WSS

The Pandemic Treaty must support building strong health systems

Cord blood banking comes at a high cost to babies

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Letters to First Opinion on caregivers, digital health, and more

Readout Newsletter: New research from Sanofi, Regeneron, etc.

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

leisure time

fashion

The need-to-know this morning

Is it time to worry about Moderna?

leisure time

Jerome Adams on the need for new antivirals for Covid

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Psychedelics group wrestles with new pharma identity

Change Healthcare can notify patients about the breach, HHS says

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Eli Lilly to pay $200M for Beam’s stake in gene

How one medical school became remarkably diverse

Eli Lilly to pay $200M for Beam’s stake in gene

Medicare details structure of new drug price negotiation program

See how much Covid

knowledge

Senate panel to vote on hospitals, PBMs, prisoner care

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Shifting the focus from loneliness to social health

Change Healthcare can notify patients about the breach, HHS says

focus

knowledge

Wikipedia

entertainment